Bioequivalence study of Rosuvastatin 40mg tablet of Cosar Pharm Co., IRAN

A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Rosuvastatin 40mg tablet of Cosar Pharm Co., IRAN and Crestor 40mg tablet of Astra-Zeneca in 24 healthy adult subjects under fasting condition

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190706044111N19

Enrollment

Registered

2020-09-27

Start date

2020-09-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia. Hyperlipidemia, unspecified

Interventions

Intervention 1: Intervention group: Single dose of one Rosuvastatin 40mg tablet of Cosar Pharm Co., IRAN. Intervention 2: Control group: Single dose of one Crestor 40mg tablet of AstraZeneca.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: - Aged between 18 - 50 years - Body weight between 50 – 100 kg - Having good health on the basis of medical history and physical & clinical examination - Understand the procedures and give written informed consent

Exclusion criteria

Exclusion criteria: Subject had undergone surgery of the gastro-intestinal tract Subject had donated a unit of blood or participated in another clinical trial, within the last two months before the first treatment. Subject had a history of drug or alcohol abuse. Subject who smokes more than 10 cigarettes per day. Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.

Design outcomes

Primary

Measure	Time frame
Plasma concentration of Rosuvastatin. Timepoint: at 0 (before dosing), 1.0, 2.0, 3.0, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 24.0 & 48.0 hr. after dosing. Method of measurement: High Performance Liquid Chromatography (HPLC).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLadan Tayebi

Pars Biopharmacy Research Co.

l.tayebi@parsbiopharmacy.com+98 21 8895 6061

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026